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Abstract
Induction of molecular chimerism through genetic modification of bone marrow is a powerful tool
for the induction of tolerance. Here we demonstrate for the first time that expression of an
allogeneic MHC class II gene in autologous bone marrow cells, resulting in a state of molecular
chimerism, induces tolerance to MHC class II mismatched skin grafts, a stringent test of transplant
tolerance. Reconstitution of recipients with syngeneic bone marrow transduced with retrovirus
encoding H-2I-Ab (I-Ab) resulted the long-term expression of the retroviral gene product on the
surface of MHC class II-expressing bone marrow derived cell types. Mechanistically, tolerance
was maintained by the presence of regulatory T cells, which prevented proliferation and cytokine
production by alloreactive host T cells. Thus, the introduction of MHC class II genes into bone
marrow derived cells through genetic engineering results in tolerance. These results have the
potential to extend the clinical applicability of molecular chimerism for tolerance induction.
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INTRODUCTION
Transplantation tolerance, defined as long-term allograft survival without ongoing
immunosuppression, remains a major goal in the field of transplantation medicine. Bone
marrow derived hematopoietic cells have been shown to be capable of inducing
transplantation tolerance (1, 2), and tolerance to allogeneic transplants in adults can be
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established by inducing a state of mixed hematopoietic chimerism through allogeneic bone
marrow transplantation (2, 3). Mixed chimerism leads to specific tolerance, and permits
transplantation of organs matched to the donor bone marrow without immunosuppression
(4). However, the use of allogeneic bone marrow transplantation to induce tolerance is
associated with serious complications, (5-11). In addition, it has been difficult to reliably
establish a stable state of mixed host-donor hematopoietic chimerism in primates (12-15).
Further decreasing the clinical applicability of bone marrow chimerism as an approach to
tolerance induction, it has been reported that induction of mixed chimerism through bone
marrow transplantation is unable to prevent chronic allograft rejection (16), currently the
major factor limiting long-term survival of transplants (17-19).
As an alternative to mixed chimerism, gene therapy approaches can be used to express
alloantigens in syngeneic bone marrow cells, resulting in molecular rather than cellular
chimerism. The induction of molecular chimerism avoids several of the serious
complications associated with mixed cellular chimerism. Because genetically engineered
bone marrow cells are of host origin, there is no possibility risk of graft vs. host disease in
which allogeneic T cells attack the host tissues (20). The possibility of generating full donor
chimerism, which results in immuno-incompetence because developing T cells are selected
on host thymic epithelium, but must respond to pathogens in a donor-MHC restricted
fashion (11), does not exist in molecular chimeras since all engineered bone marrow derived
cells express both host and donor MHC molecules. Finally, the difficulty in obtaining a
suitable bone marrow donor is avoided since syngeneic bone marrow cells are modified to
induce tolerance. These advantages suggest that the induction of molecular chimerism may
have clinical applicability in the induction of tolerance.
Tolerance to self is maintained through central mechanisms involving negative selection of
self-reactive T cells in the thymus and peripheral mechanisms involving regulatory T cells
(Tregs) (21-23). Indeed, it is clear that tolerance to self requires both a central and peripheral
component (21). We have previously demonstrated that MHC class I molecular chimerism
can induce permanent tolerance to MHC class I mismatched heart and skin allografts
(24-26) through both central and peripheral mechanisms (24, 26-29). Notably, chronic
rejection of cardiac allografts was not observed in this model. Furthermore, we have
demonstrated that tolerance to cytoplasmically expressed antigens can also be induced
through molecular chimerism (30). However, to date there have been no reports of
successfully inducing tolerance to MHC class II alloantigens through molecular chimerism.
To extend the applicability of molecular chimerism for tolerance induction, we examined
whether retrovirally mediated expression of MHC class II could induce durable tolerance.
RESULTS
Efficient transduction of bone marrow with retroviruses encoding MHC class II I-Ab
To generate retroviral vectors encoding H-2I-Ab (I-Ab), constructs were prepared in which
the cytoplasmic tail of the beta chain of I-Ab was fused to enhanced GFP (GFP) to facilitate
tracking of MHC class II chains in hematopoietic cells, as previously described (31). I-Ab
beta chain–GFP fusion genes were then cloned into the pMMP retroviral vector. Next, the
full-length cDNA encoding the alpha chain of I-Ab was cloned into the pMMP-I-Ab vector,
downstream of an IRES sequence, to generate a bicistronic vector (Figure 1A). This vector
encodes the I-Ab beta chain fused to GFP, and the alpha chain of I-Ab. The pMMP (32)
vector encoding GFP alone was used as a control in all experiments (Figure 1A). VSV-G
protein enveloped retroviruses were generated in 293T cells by transient transfection of
constructs as previously described (24), hereafter referred to as VSV-IAb, and VSV-GFP
respectively.
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To validate the ability of VSV-IAb to confer expression of I-Ab, A20 (H-2d) cells were
transduced with VSV-IAb. After 48 hours, cells were stained with a monoclonal antibody
specific for I-Ab (AF6-120.1) and analyzed by flow cytometry. Expression of GFP was used
as a marker of viral transduction. We observed that GFP+ A20 cells expressed detectable
levels of I-Ab α chain on the cell surface (Figure 1B). We next stained A20 cells transduced
with VSV-IAb with a monoclonal antibody that specifically recognizes the I-Ab α/β -
peptide complex (KH74 (33)). We observed significant expression of the I-Ab complex on
the surface of A20 cells that were GFP+ (Figure 1B). These results indicate that VSVIAb
confers expression of both the alpha and beta chains of I-Ab, and that these retrovirally-
encoded proteins are expressed on the cell surface. To determine the ability of VSV-IAb
retrovirus to infect primary murine bone marrow cells, we used GFP as a pseudomarker of I-
Ab expression. Bone marrow from 5-FU treated B10.MBR mice was isolated and transduced
with either VSV-IAb or VSVGFP retrovirus. After 72 hours, GFP expression was analyzed
by flow cytometry. Mock transduced bone marrow was used as a staining control.
Transduction of B10.MBR bone marrow with VSV-IAb led to expression of GFP in
12.7±3% of cells (Figure 1C). Transduction of bone marrow with VSV-GFP led to
expression of GFP in 29.7±14.7% of cells (Figure 1C). GFP was expressed in cells
following transduction of bone marrow with either VSV-IAb or control virus VSV-GFP at a
consistently high level suggesting that I-Ab is not inherently unstable in these cells as has
been previously reported (34). However, the median fluorescent intensity of GFP in bone
marrow cells transduced with VSV-GFP was higher than in VSV-IAb transduced cells,
reflecting lower expression of GFP when expressed as a fusion with I-Ab β chain as
observed previously (31).
Mice reconstituted with bone marrow transduced with VSV-IAb exhibit long-term
expression of retrovirally-encoded MHC class II in multiple hematopoietic lineages
We next examined expression of virally encoded MHC class II in the peripheral blood of
B10.MBR mice reconstituted with VSV-IAb, or mock transduced syngeneic bone marrow
eight weeks after bone marrow transplantation. We observed GFP expression in 20±6% in
CD4+ cells, 24±9% of CD8+ cells, 41±4% of Mac-1+ cells, 29±6% of B220+ cells and
43±8% of CD11c+ cells (Figure 2A) in mice that received VSV-IAb transduced bone
marrow. As expected there was no GFP expression in mock transduced controls. We next
examined the expression of I-Ab on the cell surface of transduced GFP+ PBMC. 10 weeks
after reconstitution, PBMC were harvested and treated with LPS for 48 hours to increase
MHC class II expression. Cells were then stained with antibodies specific for B220, I-Ab
and endogenous I-Ak. In GFP+ transduced B220+ B cells from mice that received VSV-IAb
transduced bone marrow, detectable levels of I-Ab were observed (Figure 2B), suggesting
that the products of the retrovirally encoded MHC class II genes were expressed on the cell
surface. GFP negative cells from the same animals did not express I-Ab. Moreover, we did
not observe expression of I-Ab on cells from control mice reconstituted with VSV-GFP
transduced bone marrow. Thus, VSV-IAb specifically confers I-Ab expression in progeny of
transduced progenitors. Expression of retrovirally encoded MHC class II I-Ab did not
measurably affect expression of the endogenous I-Ak chain. GFP+ and GFP- cells from the
same animal expressed similar levels of I-Ak chain expression regardless of expression of I-
Ab (Figure 2B). When CD4 and CD8 T cells were examined, we were unable to detect I-Ab
expression on the cell surface, as expected, since in mice T cells do not express MHC class
II (Figure 2B). Thus, our retroviral construct conveyed cell surface expression of allogeneic
MHC class II only in MHC class II-expressing cell types.
To analyze long-term long term expression of I-Ab in recipients of VSV-IAb transduced
bone marrow cells, B10.MBR recipients were reconstituted with 4×106 VSV-IAb or mock
transduced bone marrow cells. After 24 weeks animals were sacrificed, and expression of
Jindra et al. Page 3
Gene Ther. Author manuscript; available in PMC 2013 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
GFP and I-Ab was analyzed by flow cytometry. Detectable levels of GFP were observed in
the spleen of animals reconstituted with bone marrow transduced with VSV-IAb (Figure
2C). Mice reconstituted with VSV-IAb transduced bone marrow also expressed GFP in bone
marrow, thymus, blood and lymph nodes (data not shown). As expected, GFP was not
expressed in cells from animals reconstituted with mock transduced bone marrow cells.
Taken together, these data indicate that long-term, cell surface expression of retrovirally-
encoded MHC class II was achieved.
Expression of retrovirally encoded I-Ab induces tolerance to MHC class II mismatched skin
allografts
To determine the ability of retrovirally encoded I-Ab to induce immunologic tolerance,
B10.MBR (Kb I-Ak, I-Ek Dq) mice were reconstituted with VSV-IAb or VSV-GFP
transduced bone marrow. After eight to ten weeks, mice reconstituted with either VSV-IAb
or VSV-GFP transduced bone marrow received both a MHC class II mismatched B10.QBR
(Kb, I-Ab,I-Enull, Dq) and a third-party BALB/c (H-2d) skin graft. B10.MBR mice
reconstituted with VSV-GFP transduced bone marrow rapidly rejected both B10.QBR
(Figure 3A, median survival time (MST)= 14 days, n=12) and BALB/c skin grafts (Figure
3B, MST= 16 days, n=12). In contrast mice reconstituted with VSV-IAb transduced bone
marrow accepted B10.QBR skin grafts long term (Figure 3A, MST>100 days, n=9, p <
0.006), but rejected third party BALB/c skin grafts rapidly (Figure 3B, MST= 14 days, n=9)
indicating that tolerance was specific to grafts expressing I-Ab.
Decreased T cell proliferation in response to allogeneic stimulators in mice expressing
retrovirally-encoded allogeneic MHC class II
We next examined the effect of expressing retrovirally encoded I-Ab on proliferation of
alloreactive T cells. B10.MBR mice reconstituted with VSV-IAb or control VSV-GFP
transduced bone marrow were immunized with 107 irradiated B10.QBR splenocytes. After
10 days, splenocytes were harvested, stained with CFSE and cultured with irradiated
B10.QBR or BALB/c splenocytes for 72 hours. T cells derived from mice reconstituted with
VSV-GFP transduced bone marrow proliferated in response to either B10.QBR or third
party BALB/c splenocytes (Figure 4, p <0.001 in comparison to syngeneic stimulators). In
contrast, T cells derived from mice reconstituted with bone marrow transduced with VSV-
IAb did not proliferate when cultured with B10.QBR stimulators, although they did
proliferate in response to third party BALB/c splenocytes (Figure 4, p <0.05 in comparison
to syngeneic stimulators), suggesting that suppression of T cell proliferation is specific. The
response of splenocytes from mice reconstituted with bone marrow transduced with VSV-
IAb to third party BALB/c splenocytes appeared to be lower than that of mice reconstituted
with VSV-GFP transduced bone marrow, although this did not reach statistical significance
(Figure 4, p > 0.05). However, mice reconstituted with bone marrow transduced with VSV-
IAb were able to rapidly reject skin grafts from BALB/c mice (Figure 3B), suggesting that
responses to third party antigens remain intact in these mice.
Induction of molecular chimerism prevents cytokine production by alloreactive T cells
We next determined the ability of T cells from B10.MBR mice reconstituted with VSV-IAb
or VSV-GFP transduced bone marrow to produce effector cytokines following stimulation
with irradiated MHC class II mismatched B10.QBR splenocytes. B10.MBR mice were
reconstituted with VSV-IAb or VSV-GFP transduced bone marrow as described above and
then sacrificed eight to ten weeks after reconstitution. Splenocytes were harvested and
cultured for 48 hours together with irradiated B10.QBR splenocytes. To measure the
alloreactive response, production of IL-2, IL-4, or IFN-γ was analyzed by performing
cytokine ELISPOT assays. We observed relatively few IL-2 (13 ± 4 vs. 661 ± 52 per 106),
IL-4 (28 ± 10 vs. 208 ± 20 per 106) and IFN-γ (0.67± 0.58 vs. 88 ± 60 per 106) producing
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cells (Figure 5A) in the spleens of mice reconstituted with VSV-IAb transduced bone
marrow when compared to the number observed in the spleens of mice reconstituted with
VSV-GFP transduced bone marrow (p <0.05 between groups).
We next analyzed cytokine production using multiplex Luminex assays. B10.MBR mice
were reconstituted with VSV-IAb or VSV-GFP transduced bone marrow as described
above. Eight to ten weeks after reconstitution, animals were sacrificed, and splenocytes were
cultured for 48 hours with irradiated B10.QBR splenocytes. After 48 hours, cell culture
supernatants were harvested and production of GM-CSF, IFNγ, IL12 (p70), IL-17, IL-2,
IL-4, IL-5, IL-6, IL-10, MIP-1α, RANTES, and TNFα examined by LUMINEX. When
supernatants from cells derived from mice reconstituted with VSV-IAb transduced bone
marrow were examined, significantly lower levels of GM-CSF, IFNγ, IL-17, IL-2, IL-4,
IL-5, IL-6, IL-10, MIP-1α, and TNFα were produced when compared with supernatants
from cells derived from mice reconstituted with VSV-GFP transduced bone marrow (p
<0.05 between groups for each cytokine pair, Figure 5B). Taken together these data suggest
that expression of retrovirally encoded I-Ab in molecular chimeras significantly impairs the
production of cytokines in response to I-Ab-expressing allogeneic stimulators.
Regulatory T cells are required for long-term skin graft acceptance
We have previously shown that tolerance induction through molecular chimerism has both a
deletional and a regulatory component (24, 25, 27). To test the degree to which regulatory T
cells were involved in tolerance to MHC class II mismatched skin grafts, B10.MBR mice
were reconstituted with syngeneic bone marrow transduced with VSV-IAb as described.
Eight weeks after reconstitution mice were challenged with a B10.QBR skin graft. As
previously observed, B10.MBR mice reconstituted with bone marrow transduced with VSV-
IAb accepted B10.QBR skin grafts indicating they were tolerant to I-Ab. 55 days after skin
grafting, tolerant mice expressing retrovirally encoded I-Ab were then injected with the anti-
CD25 antibody PC61. Antibody treatment effectively reduced the frequency of CD4+CD25+
Treg cells in the blood of B10.MBR reconstituted with bone marrow transduced with VSV-
IAb (Figure 6A). We also found that FoxP3+ cells were effectively depleted from blood of
these animals (11%±1% of CD4 T cells were FoxP3+ prior to administration of PC61,
compared with 6%±2% after administration P<0.02). No significant difference was observed
in the total frequency of CD4+CD25+ Treg in mice reconstituted with bone marrow
transduced with VSV-IAb when compared with bone marrow transduced with VSV-GFP
(Figure 6A). We confirmed that in our system >95% of CD4+CD25+ T cells were also
positive for FoxP3 by intracellular staining and flow cytometry (data not shown). B10.MBR
mice reconstituted with bone marrow transduced with VSV-IAb rejected their skin grafts
rapidly following treatment with anti-CD25 antibody (Figure 6B MST= 17 days relative to
the initiation of antibody treatment, n=6 p < 0.01 in relation to animals that did not receive
PC61). These data suggest that regulatory T cells are involved in maintenance of tolerance
to MHC class II mismatched skin grafts. In the absence of anti-CD25 antibody treatment,
skin grafts are accepted for the life of the animal, suggesting that MHC class II gene therapy
prevents chronic rejection of skin.
DISCUSSION
There has been a great deal of interest in using gene therapy to induce a state of tolerance in
the context of restoring normal immune responses in autoimmune models (35-46), in
eliminating immune responses to introduced transgenes in the context of replacement gene
therapy (47-49), and in inducing tolerance to allergens (50). These approaches focus on the
introduction of a single antigen which is then presented to the immune system on host MHC
molecules in genetically modified cells. The presentation of these single antigens on bone
marrow derived cells, B cells (43, 44, 51, 52), T cells or dendritic cells (53) has been shown
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to reproducibly induce tolerance in many models. However, in the transplantation setting,
rejection of an allogeneic organ is not mediated by a single antigen difference, but rather
through the recognition of a multitude of self-antigens and alloantigens in the context of
allogeneic MHC. This can occur directly on donor cells (direct presentation), or through
antigen processing and presentation on host cells (indirect presentation). The combination of
direct and indirect presentation results in a high precursor frequency of cells capable of
responding to the allogeneic organ, thus presenting a particular challenge to the induction of
tolerance.
We have previously shown that the induction of molecular chimerism can be used to induce
tolerance (24, 31, 54). In the setting of transplantation, we have shown that inducing
molecular chimerism can be used to induce tolerance to MHC class I mismatched allografts
(24, 25, 27). Mechanistically, tolerance to MHC class I induced through molecular
chimerism occurs through both central deletion of alloreactive T cells (27) and through the
induction of regulatory T cells (25). These results demonstrate that molecular chimerism is a
powerful tool for the induction of tolerance without the need for extensive conditioning (55),
and without the possibility of inducing complications such as GVHD since the bone marrow
is syngeneic. However, for clinical transplantation it would be highly desirable to induce
tolerance to both MHC class I and MHC class II mismatched organs. We therefore set out to
determine whether molecular chimerism with donor MHC class II molecules had an equal
capacity to induce long-term tolerance in an allogeneic system.
Our bicistronic retroviral construct encoding MHC class II α and β chains confers cell
surface expression of I-Ab on transduced A20 cells without reducing cell surface expression
of endogenous I-Ak α chain. The levels of endogenous I-Ak detected on transduced cells
was higher than the level of I-Ab. While it is possible that retrovirally encoded MHC class II
is less efficiently expressed than the endogenous chains, we suggest that it is more likely
that the observed effect is due to the presence of k/b heterodimers on the cell surface as has
previously been reported when α/β chain expression is driven by a strong exogenous
promoter (56). Our I-Ab specific antibody recognizes I-Ab when complexed with peptide,
while the antibody used to detect I-Ak α recognizes both b/k and k/k dimers present on the
cell surface. Thus we suggest that increased levels of I-Ak observed may be due to increased
detection.
Unlike MHC class I which is expressed on all nucleated cells, MHC class II expression is
restricted to a subset of cells including antigen presenting cells such as B cells,
macrophages, and dendritic cells (reviewed in (57)). Cell surface expression of MHC class II
in these cells is tightly regulated (reviewed in (58)). When bone marrow transduced with
VSV-IAb was used to reconstitute conditioned recipients, we observed expression of GFP in
all cell lineages examined. However, cell surface expression of I-Ab was observed only on
MHC class II expressing cell types. We suggest that the restriction of I-Ab expression to
antigen presenting cells is due to the requirement for the cellular machinery that allows for
MHC class II expression. Furthermore, we found that expression of the retrovirally encoded
MHC class II was inducible. When cells from mice reconstituted with bone marrow
transduced with VSV-IAb were examined directly ex vivo, only low levels of retrovirally
encoded MHC class II were detected on the surface. However, when cells were stimulated
with LPS, expression of MHC class II was up-regulated in fashion similar to endogenous
MHC class II. This suggests that the induction of MHC class II in primary cells is controlled
by cellular mechanisms unrelated to prevalence of mRNA encoding MHC class II. Taken
together, these data suggest that retrovirally encoded MHC class II genes are expressed on
the cell surface in a physiologically relevant manner.
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Our data demonstrate that reconstitution of mice with VSV-IAb transduced bone marrow
results in long-term multi-lineage expression of retrovirally-encoded genes. This point is of
particular importance, since we have previously demonstrated that long-term expression of
antigen is critical for tolerance induction in molecular chimeras (59). Indeed, long-term
multilineage expression of retrovirally encoded I-Ab resulted in long-term acceptance of I-
Ab expressing B10.QBR skin allografts. Acceptance of skin grafts is a robust measurement
of tolerance induction, and therefore this finding indicates that inducing expression of MHC
class II molecules through genetic engineering of autologous bone marrow results is an
effective and robust approach that can result in tolerance to allografts.
In contrast to our results, LeGuern et al. have recently reported that expression of MHC
class II on bone marrow derived cells is not sufficient to induce tolerance (34). These
authors found that the primary T cell response to MHC class II was unchanged in mice
receiving MHC class II transduced bone syngeneic marrow. However, they were able to
observe prolongation of heart allografts following depletion of CD8 T cells in mice
reconstituted with bone marrow transduced with virus encoding I-A, similar to what had
previously been observed following CD4 T cell depletion(60). In contrast, we were able to
observe long-term survival of skin grafts without the requirement for T cell depletion, a
much more rigorous test of tolerance. Thus while we observed tolerance induction, the
LeGuern et al. posited only an increase in the generation of regulatory T cells. Notably
LeGuern et al. failed to obtain cell surface expression of MHC class II, and expression of
MHC class II intracellularly (as measured by GFP as a pseudomarker) was rapidly
extinguished. We therefore suggest that, since long-term antigen expression is required for
the induction of tolerance (61), the failure to achieve tolerance in this study is related to a
failure to achieve substantial long-term MHC class II expression. Our study shows that it
would be incorrect to interpret the results of LeGuern et al. (34), and previous work by the
same group in large animal models (62) to demonstrate that molecular chimerism with MHC
class II fails to induce tolerance, but only that as we have demonstrated, long-term
expression of retrovirally encoded products is required.
We have previously shown that induction of tolerance to MHC class I antigens through
molecular chimerism results in deletion of alloreactive T cells in the thymus, and the
generation of regulatory T cells (25). Depletion of regulatory T cells did not disrupt skin
graft tolerance, indicating that central deletion is dominant in the case of mice rendered
tolerant to MHC class I following induction of molecular chimerism. Here we have shown
induced skin graft tolerance to MHC class II can be reversed through the depletion of
CD25+ cells, suggesting that in an MHC class II model of molecular chimerism, regulatory
T cells are required for tolerance. In contrast to the assertion by LeGuern et al. that donor
specific transfusion is required to “activate” Treg in vivo in mice receiving MHC class II
transduced bone marrow (34), our data show that in molecular chimeras, Tregs develop
which are directly involved in controlling alloreactive T cell responses. We note that the
level of MHC surface expression we were able to achieve may facilitate more efficient Treg
generation.
CD4+ regulatory T cells can be either Foxp3+ regulatory T-cells (Tregs) and IL-10-
producing regulatory type I (Tr1) cells. Activated Tr1 cells can express CD25, and are
characterized by a unique pattern of cytokine expression consisting primarily of IL-10, TGF-
β and IL-5 (63-65). While no specific markers allow us to unambiguously distinguish Tr1
cells, we would suggest that Tr1 cells are probably not involved in this model, as we do not
detect significant amounts of IL-10.
Our results demonstrate that genetic modification of syngeneic hematopoietic stem cells to
express allogeneic MHC genes can be used to facilitate tolerance to allografts, essentially
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resulting in matching at MHC class I and II. Given that MHC matching results in profound
improvements in long-term survival of allogeneic transplants we suggest that the use of gene
therapy may represent one way to improve organ allograft survival.
MATERIALS AND METHODS
Mice
B10.MBR (Kb, I-Ak,I-Ek, Dq), and BALB/c (H-2d) mice were purchased from The Jackson
Laboratory (Bar Harbor, ME). B10.QBR (Kb, I-Ab,I-Enull, Dq) mice were bred in our
facility. Mice were housed under microisolator conditions in autoclaved cages and
maintained on irradiated feed and autoclaved acidified drinking water. Four to six week old
female mice were used in all experiments. All experiments were performed in accordance
with the humane use and care policies of our Institution.
Monoclonal antibodies and Flow Cytometry
All cell surface staining and flow cytometry was performed as described previously (66, 67).
Monoclonal antibodies (mAbs) specific for CD4 (L3T4), CD8 (52-6.7), I-Ab (KH74 or
AF6-120.1), I-Ak (11.5-2), CD25 (7D4), CD11b (Mac-1, M1/70), CD11c (HL3) and B220
(RA3-6B2) were obtained from BD PharMingen (San Diego, CA). FoxP3 staining kit was
obtained from eBioscience (San Diego, CA). Depleting/inactivating anti-CD25 (PC61)
antibody was the kind gift of Dr. Mohamed Sayegh (Brigham and Women's Hospital,
Boston).
Retroviruses
The full-length cDNA encoding H-2 I-Ab alpha chain was cloned into the MMP retroviral
vector containing the I-Ab beta chain fused to enhanced green fluorescent protein (eGFP)
previously described (31) to generate pMMP-I-Ab. VSV-G envelope protein pseudotyped
viruses were prepared by packaging the pMMP-I-Ab vector in 293T cells by transient
transfection, and titered as described (31).
Retroviral transduction of bone marrow cells
Bone marrow cells were harvested from B10.MBR mice and transduced as described
previously (67). Briefly, bone marrow cells from mice treated 7 days before with 150 mg/kg
5-Fluorouracil were cultured in tissue culture plates coated with Retronectin (Takara
Biomedicals, Shiga, Japan) and transduced in Dulbecco minimum essential medium
containing 15% lot-tested fetal calf serum and cytokines to achieve a final concentration of
100 ng/ml human interleukin 6 (IL-6; R&D Systems, Minneapolis, MN), 100 ng/ml
recombinant mouse stem cell factor (R&D Systems), 50 ng/ml recombinant mouse
thrombopoietin (R&D Systems), and 50 ng/ml recombinant mouse Flt-3 ligand (R&D
Systems). All transductions were performed at 37°C with 5% CO2 for 96 h. Viral
supernatants and transduction media were replaced after 72 h. After 96 hours, the cells were
harvested, washed twice in Hanks’ balanced salt solution, and counted.
Bone marrow transplantation
Mice were conditioned with 11Gy whole-body irradiation 1 day prior to bone marrow
transplantation. On the day of reconstitution, 4×106 transduced B10.MBR bone marrow
cells were injected into the tail vein of recipient mice.
Mixed Lymphocyte Reaction
B10.MBR mice reconstituted with transduced bone marrow as above were immunized
intraperitoneally (i.p.) with an injection of 107 irradiated (25 Gy) B10.QBR splenocytes. Ten
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days after immunization, animals were sacrificed and splenocytes were harvested.
Splenocytes were stained with 0.1μM CFSE (Invitrogen, Carlsbad CA) for 8 min at room
temperature and cultured in the presence of irradiated (25 Gy) B10.QBR splenocytes or third
party BALB/c splenocytes for 96 hrs. Cell proliferation of CD4 and CD8 T cells was
assessed by flow cytometry. Percent proliferation was calculated using FloJo software
proliferation platform.
ELISPOT Assays
Eight to 12 weeks after B10.MBR mice were reconstituted with transduced bone marrow,
recipients were immunized i.p. with 107 irradiated (25 Gy) B10.QBR splenocytes. Ten days
later animals were sacrificed and single-cell suspensions of splenocytes were prepared and
used in a standard cytokine ELISPOT assay as described (66). ELISPOT data are presented
as the number of cytokine producing cells per 106 T cells.
Luminex
Luminex assays were performed using the Millipore (Billerica, MA) Milliplex Mouse 12
Cytokine/Chemokine Panel kit according to the manufacturer's instructions. Cytokine profile
was analyzed on Luminex 100™ (Luminex Corporation, Austin, TX) based on
manufacturer's instructions. Duplicate wells were used for each sample.
Skin grafting
Tail skin grafting was performed by a modification of a method previously described (67).
Full-thickness tail skin grafts were harvested from the tails of B10.QBR or BALB/c mice.
Recipients were anesthetized with 250 mg/kg Avertin and grafted without suturing onto
prepared sites on the flanks. Skin grafts were dressed with Vaseline-impregnated gauze and
an adhesive bandage for the first 7 days after surgery. Thereafter, skin grafts were assessed
three times weekly, and rejection was defined as the first day on which the entire graft
surface appeared necrotic.
Statistical Analysis
All statistical calculations were preformed using GraphPad Prism 4.0a software (Graphpad
Software, San Diego, CA). The Kaplan and Meier method with a 95% CI was used for the
calculation of survival curves. Survival curves were compared using the log rank test. P
values <0.05 using Student's t test were considered statistically significant.
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Figure 1. Bicistronic retroviral vector encoding MHC class II confers cell surface expression of I-
Ab, and transduces murine bone marrow
(A) Schematic of the bicistronic retroviral construct containing the I-Ab β gene fused to
GFP, an internal ribosomal entry site and I-Ab α. Control virus encodes GFP alone (B) A20
cells were transduced with VSV-I-Ab (right panels) or mock transduced (left panels) and cell
surface expression of the I-Ab α chain (upper panels) or the I-Ab/ peptide complex (lower
panels) was measured by cell surface staining and flow cytometry. Mock transduced A20
cells were used as staining controls. (C) Bone marrow cells were harvested from mice
treated 7 days prior with 5-FU, and transduced with VSV-GFP control virus (left panel) or
VSV-I-Ab(right panel). 72 hours later, transduction was monitored via GFP fluorescence
and flow cytometry. Shown is one representative of three independent experiments.
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Figure 2. Long-term multi-lineage expression of retrovirally encoded proteins
(A) 4 weeks after reconstitution with bone marrow transduced with VSV-I-Ab (left column)
or mock transduced (right column), B10.MBR mice were bled, and peripheral blood
mononuclear cells (PBMC) were examined by cell surface staining with the lineage markers
CD4, CD8, B220, CD11b and CD11c. Cells were then analyzed by flow cytometry. Shown
is one representative of three independent experiments. (B) 11 weeks mice were
reconstituted with bone marrow transduced with VSV-I-Ab, PBMC were harvested and
stimulated with LPS. After 72 hours, cells were stained with antibodies specific for IAb, IAk,
B220 and CD3 prior to analysis by flow cytometry. Shown are B220+ cells (upper panels)
gated on transduced GFP+ cells (solid black line) or GFP- cells (solid gray line. Cells from
naïve B10.MBR stimulated with LPS were used as a control (dashed line). Also shown are
GFP+ (black line) and GFP- (gray line) CD3+ T cells (lower panel). (C) 24 weeks after bone
marrow reconstitution, recipients of VSV-I-Ab (left panel) or mock (right panel) transduced
bone marrow were bled, and GFP and IAb expression in lymphocytes was analyzed by flow
cytometry. Shown is one representative of three independent experiments.
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Figure 3. Expression of retrovirally encoded MHC class II proteins induces specific tolerance to
skin grafts
(A) 8-10 weeks after bone marrow reconstitution, B10.MBR recipients of VSV-I-Ab
(triangles) or VSV-GFP (squares) transduced bone marrow received MHC class II
mismatched B10.QBR skin grafts. (B) B10.MBR recipients of VSV-I-Ab (triangles) or
VSV-GFP (diamonds) transduced bone marrow also received BALB/c skin grafts. Shown
are the combined results of 3 independent experiments.
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Figure 4. Expression of retrovirally encoded MHC class II prevents T cell proliferation in
response to MHC class II mismatched splenocytes
B10.MBR mice were reconstituted with VSV-I-Ab (I-Ab) or control VSV-GFP (GFP)
transduced bone marrow. Recipients were immunized with 107 irradiated B10.QBR
splenocytes and then sacrificed 10 days later. (A) Splenocytes were CFSE labeled and
stimulated with irradiated syngeneic B10.MBR (dotted line), or allogeneic B10.QBR (solid
line)or BALB/c dashed line. Proliferation was monitored by flow cytometry after 72 hours.
(B). The results of the experiment in panel A expressed percent proliferation. VSV-I-Ab
(white bars) or VSV-GFP (black bars). Shown is one representative experiment of two. Each
experiment assayed 2-3 individual mice per group.
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Figure 5. Expression of retrovirally encoded MHC class II prevents T cell cytokine production in
response to MHC class II mismatched splenocytes
B10.MBR mice were reconstituted with VSV-I-Ab (white bars) or control VSV-GFP (black
bars) transduced bone marrow. 8-10 weeks after reconstitution, mice were immunized with
107 irradiated B10.QBR splenocytes and sacrificed 10 days later. (A) Splenocytes were re-
stimulated with irradiated B10.QBR splenocytes and analyzed by ELISPOT for IL-2, IL-4
or IFN-γ. Data are presented as spots per 106 T cells for each cytokine examined. Shown are
the cumulative mean values and standard deviations obtained from three separate
experiments. (B) Splenocytes were re-stimulated with B10.QBR or syngeneic B10.MBR
splenocytes, and after 48 hours, supernatants were collected and analyzed for cytokine
expression by Luminex assay. Background response to B10.MBR has been subtracted from
the results shown. Shown are the cumulative mean values and standard deviations obtained
from three separate experiments.
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Figure 6. Tolerance induced by retrovirally encoded MHC class II is dependent on regulatory T
cells
A. Frequency of CD4+CD25+ T cells in mice that received VSV-GFP (GFP) or VSV-I-Ab
before and after administration of PC61. Immediately prior to injection with PC61,
recipients of bone marrow transduced with VSV-GFP (GFP) or VSV-I-Ab were bled, and
PBMC were examined by cell surface staining and flow cytometry for expression of CD4
and CD25. N=5 for all groups B. 4 weeks after bone marrow reconstitution, B10.MBR
recipients of VSV-I-Ab transduced bone marrow received MHC class II mismatched
B10.QBR skin grafts. 56 days after skin grafting, mice were treated with anti-CD25
antibody PC61 (0.125 mg/mouse administered every other day), circles. N=6 Control mice
that did not receive antibody are represented by squares. N=8. Shown are combined results
of three independent experiments.
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